Trimethoprim-Sulfamethoxazole Prophylaxis Reduced Rituximab Infection Risk

Severe infections occurred in 25% of patients with anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) who were treated with rituximab, according to results of an observational study conducted in the United Kingdom (U.K.) and Austria. Trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis, however, reduced the risk of severe infections, the investigators reported in Annals of the Rheumatic Diseases.1 Andreas... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Drug Updates Vasculitis antibody-associated vasculitis Infection rituximab Source Type: research